ArticleJournal of Brown hospital medicine2026
Cyclic Thrombocytopenia Complicated by Thrombosis and Successfully Treated With Rituximab: A Diagnostic and Therapeutic Challenge.
Article in Journal of Brown hospital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclic thrombocytopenia (CTP) is a rare hematologic disorder characterized by fluctuating platelet counts and is often misdiagnosed as immune thrombocytopenia. We present the case of a 51-year-old woman with a history of severe thrombocytopenia and mucocutane-ous bleeding since 2012, initially treated as immune thrombocytopenia with corticoster-oids, splenectomy, and azathioprine, without sustained response. Over time, she devel-oped pronounced cyclic fluctuations in platelet counts (<10,000/mm³ to >150,000/mm³) every 21 days. Treatment with eltrombopag resulted in deep venous thrombosis and a major pulmonary bleeding episode associated with anticoagulation. After secondary causes and bone marrow disorders were excluded, cyclic thrombocytopenia was diag-nosed. Rituximab (375 mg/m² weekly for four weeks) led to a significant reduction in platelet oscillations, with no further significant bleeding. This case highlights the diagnos-tic challenges of CTP, underscores the thrombotic risks of thrombopoietin receptor agonists, and supports rituximab as a potential treatment for refractory cases with high thrombo-hemorrhagic risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.